ATE234084T1 - Substanzen, die mit dem thyroid-hormonrezeptor interagieren, zur behandlung fibrotischer erkrankungen - Google Patents

Substanzen, die mit dem thyroid-hormonrezeptor interagieren, zur behandlung fibrotischer erkrankungen

Info

Publication number
ATE234084T1
ATE234084T1 AT99925157T AT99925157T ATE234084T1 AT E234084 T1 ATE234084 T1 AT E234084T1 AT 99925157 T AT99925157 T AT 99925157T AT 99925157 T AT99925157 T AT 99925157T AT E234084 T1 ATE234084 T1 AT E234084T1
Authority
AT
Austria
Prior art keywords
interact
substances
treatment
hormone receptor
thyroid hormone
Prior art date
Application number
AT99925157T
Other languages
English (en)
Inventor
Michael Edward John Billingham
Janet Katherine Fernihough
Original Assignee
Arthromics Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9811784.9A external-priority patent/GB9811784D0/en
Application filed by Arthromics Plc filed Critical Arthromics Plc
Application granted granted Critical
Publication of ATE234084T1 publication Critical patent/ATE234084T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT99925157T 1998-06-02 1999-05-27 Substanzen, die mit dem thyroid-hormonrezeptor interagieren, zur behandlung fibrotischer erkrankungen ATE234084T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9811784.9A GB9811784D0 (en) 1998-06-02 1998-06-02 Fibrotic disease
GBGB9827834.4A GB9827834D0 (en) 1998-06-02 1998-12-17 Fibrotic disease
PCT/GB1999/001684 WO1999062507A1 (en) 1998-06-02 1999-05-27 Compounds which interact with the thyroid hormone receptor for the treatment of fibrotic disease

Publications (1)

Publication Number Publication Date
ATE234084T1 true ATE234084T1 (de) 2003-03-15

Family

ID=26313780

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99925157T ATE234084T1 (de) 1998-06-02 1999-05-27 Substanzen, die mit dem thyroid-hormonrezeptor interagieren, zur behandlung fibrotischer erkrankungen

Country Status (8)

Country Link
US (5) US6348497B1 (de)
EP (1) EP1083891B1 (de)
JP (1) JP2002516855A (de)
AT (1) ATE234084T1 (de)
AU (1) AU4154799A (de)
DE (1) DE69905877T2 (de)
ES (1) ES2194466T3 (de)
WO (1) WO1999062507A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8531101A (en) * 2000-08-29 2002-03-13 Nobex Corp Immunoregulatory compounds and derivatives and methods of treating diseases therewith
US8048924B2 (en) * 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
CN1882327A (zh) * 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
GB0406378D0 (en) * 2004-03-22 2004-04-21 Karobio Ab Novel pharmaceutical compositions
DK1773767T3 (en) 2004-07-07 2016-03-21 Biocon Ltd Synthesis of azo bound in immune regulatory relations
MX2007014501A (es) * 2005-05-26 2008-02-07 Metabasis Therapeutics Inc Tiromimeticos novedosos que contienen acido fosfinico.
CA2606499C (en) 2005-05-26 2017-06-13 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
JP5910099B2 (ja) 2012-01-18 2016-04-27 セイコーエプソン株式会社 干渉フィルター、光学モジュールおよび電子機器
US20190070145A1 (en) * 2016-03-22 2019-03-07 Mayo Foundation For Medical Education And Research Using fatty acid synthase inhibitors to treat fibrosis
CA3044059A1 (en) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease
BR112019025659A2 (pt) 2017-06-05 2020-08-25 Viking Therapeutics, Inc. composições para o tratamento de fibrose
AU2019238090A1 (en) 2018-03-22 2020-10-08 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB860303A (en) 1958-06-20 1961-02-01 Ici Ltd Pharmaceutical compositions comprising ª‡-aryloxy-aliphatic carboxylic acids and/or ª
GB1140748A (en) * 1966-06-23 1969-01-22 Ici Ltd New carboxylic acid derivatives
ATE1855T1 (de) * 1978-09-08 1982-12-15 Imperial Chemical Industries Plc Antiarthritische hydroxyessigsaeurederivate, pharmazeutische zusammensetzungen daraus und verfahren zu ihrer herstellung.
GB2073178B (en) * 1980-04-03 1984-01-25 Ici Ltd Dioxolane derivatives
GB2073177A (en) 1980-04-03 1981-10-14 Ici Ltd Benzaldehyde derivative
DE69116563T3 (de) 1990-09-21 2006-07-06 The Salk Institute For Biological Studies, La Jolla Durch protoonkogenischen Proteinkomplex AP-1 kontrollierte Verfahren
WO1995027202A1 (en) 1994-03-30 1995-10-12 Ciba-Geigy Ag Screening method using the rzr receptor family
EP0769146A2 (de) * 1994-07-01 1997-04-23 Ligand Pharmaceuticals, Inc. Screening von "nuc" inhibitoren
AU2332497A (en) 1996-03-19 1997-10-10 Salk Institute For Biological Studies, The (in vitro) methods for identifying modulators of members of the steroid/thyroid superfamily of receptors

Also Published As

Publication number Publication date
WO1999062507A1 (en) 1999-12-09
US20070213402A1 (en) 2007-09-13
AU4154799A (en) 1999-12-20
ES2194466T3 (es) 2003-11-16
JP2002516855A (ja) 2002-06-11
US20030018077A1 (en) 2003-01-23
US20020049254A1 (en) 2002-04-25
US20040180963A1 (en) 2004-09-16
EP1083891A1 (de) 2001-03-21
DE69905877T2 (de) 2003-11-20
DE69905877D1 (de) 2003-04-17
EP1083891B1 (de) 2003-03-12
US6348497B1 (en) 2002-02-19
US6414026B1 (en) 2002-07-02

Similar Documents

Publication Publication Date Title
ATE234084T1 (de) Substanzen, die mit dem thyroid-hormonrezeptor interagieren, zur behandlung fibrotischer erkrankungen
WO1999064059A3 (en) Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders
RU93058351A (ru) Замещенные 3-аминохинуклидины, фармацевтические композиции на его основе, способы лечения, способ получения, промежуточные соединения
EP1336600A3 (de) Dimer-selektive rxr Modulatoren und Verfahren zu ihrer Verwendung
IL130931A0 (en) Small molecules useful in the treatment of inflammatory disease
DE69942610D1 (de) Die bindung von integrinen zu deren rezeptoren verhindernde verbindungen
EP0911331A3 (de) Substutierte Dibenzoxazepinverbindungen, pharmazeutische Zusammensetzungen, und Anwendungsmethoden
NL300258I1 (nl) Farmaceutische samenstelling voor toepassing in debehandeling van diabetes.
ATE207349T1 (de) Thip zur behandlung von schlafstörungen
HUP0003591A2 (hu) Az oppozíciós ellenálló rendellenesség kezelése
MA26420A1 (fr) Compositions pharmaceutiques mixtes pour le traitement de l'osteoporose, et procede pour leur preparation.
EP1297888A3 (de) Vorrichtung zur Herstellung einer Polymerlösung
BG104357A (en) Derivatives of cyclopentene used as motiline receptor antagonists
BG104436A (en) The administration of macrolides for the treatment of cancer and macular degeneration
EP1052286A3 (de) Wachstumshormon- (GH) und Wachstumshormon-freisetzenden Hormon (GHRH) enthaltende Zusammensetzungen
PL350568A1 (en) N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
DE60015791D1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
TW231970B (de)
IL147123A0 (en) Compositions containing soluble forms of hla-g for treating inflammatory skin pathologies
ITBO950293A0 (it) Composto per il trattamento di escrementi animali
EP1050303A3 (de) Methoden und Zusammenstellungen zur Behandlung von altersgebundenen Verhaltensstörungen von Haustieren
EP0902025A3 (de) Benzothiophene zur Behandlung von Estrogen-abhängigen Erkrankungen
WO2000044408A3 (en) Method of treating demyelinating inflammatory disease using ccr1 antagonists
DZ2757A1 (fr) Procédé pour la préparation d'acides hydroxamiques.
EP1159965A3 (de) Methode zur Verhütung oder Behinderung der Fertilisation

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1083891

Country of ref document: EP

REN Ceased due to non-payment of the annual fee